Drug Reation May Predict Mesothelioma Immunotherapy Results

mesothelioma immunotherapy results

Patients who have more serious reactions to the drug nivolumab tend to have better mesothelioma immunotherapy results than those who have little or no reaction.  That is the finding of a new study from Japan’s Tokushima University.  Researchers studied the cases of 11 patients treated with nivolumab between 2009 and 2021. They found that the patients who got the sickest from the drug had the best mesothelioma immunotherapy results.  The study’s authors say it’s even more reason to find ways to manage immunotherapy side effects. If patients can work through their worst reactions, more of them might survive mesothelioma.  Nivolumab in Mesothelioma Treatment Nivolumab is an immune checkpoint inhibitor sold under the brand name Opdivo. It is a type of … Continue reading Drug Reation May Predict Mesothelioma Immunotherapy Results »

Sensitizer Could Improve Radiotherapy for Pleural Mesothelioma

radiotherapy for pleural mesothelioma

A chemical compound that sensitizes cancer cells to radiation could help improve radiotherapy for pleural mesothelioma. Radiotherapy uses ionizing radiation to scramble the DNA of cancer cells. This makes it harder for cells to replicate and form new tumors.  But mesothelioma cells and other hard-to-treat cancers have ways of protecting themselves against radiation-induced DNA damage. The possibility of damaging healthy cells is another limiting factor in radiotherapy for pleural mesothelioma.  Now, a Japanese study of mice shows a new compound called SQAP can enhance the damage to cancer cells from radiation. The researchers are hopeful it could help keep mesothelioma tumors in check. The Challenge of Radiotherapy for Pleural Mesothelioma Malignant pleural mesothelioma is difficult to treat. This aggressive membrane … Continue reading Sensitizer Could Improve Radiotherapy for Pleural Mesothelioma »

Misdiagnosis of Mesothelioma More Common with Cytology Alone

misdiagnosis of mesothelioma

A new set of case reports illustrates how easily misdiagnosis of mesothelioma can happen when the diagnosis is based on cytology alone.  Cytology tests look at the cells in body fluids. For peritoneal mesothelioma patients, this is often the fluid that collects in their abdomen called ascites.  But doctors from India’s Dayanand Medical College and Hospital say using ascites samples alone to diagnose mesothelioma is a risky practice. Misdiagnosis of mesothelioma may delay proper treatment and negatively impact survival. The Difficulty of Diagnosing Peritoneal Mesothelioma Malignant mesothelioma only impacts about 2,500 people in the US every year. It is most common among people who have lived or worked around asbestos. Peritoneal mesothelioma is even rarer. About a fifth of patients … Continue reading Misdiagnosis of Mesothelioma More Common with Cytology Alone »

Statin Drugs Support Immunotherapy for Mesothelioma, New Study Finds

statin drug

There’s more evidence that statin drugs may improve the effectiveness of mesothelioma immunotherapy.  The new study, led by Korean biochemists, is not the first to show that these anti-cholesterol medications may help mesothelioma patients. But this one goes a step further to explain why they help.  Researchers focused on the impact of statin drugs on PD-1 expression. PD-1 is a protein that protects mesothelioma cells against immune system attack.  The findings suggest that, by lowering PD-1 levels, anti-cholesterol drugs may play a greater role in the future of mesothelioma treatment.  PD-1 and Mesothelioma Immunotherapy PD-1 is an immune checkpoint protein that occurs on the surface of cells. Normally, it helps keep the immune system from attacking healthy tissues. But mesothelioma … Continue reading Statin Drugs Support Immunotherapy for Mesothelioma, New Study Finds »

Pleural Mesothelioma Patients are Stronger a Year After Surgery

pleural mesothelioma patients

Pleural mesothelioma patients can be stronger and have better lung function a year after surgery than in the days and weeks immediately following their operation. That’s the finding of Japanese researchers who just published a new study in Integrative Cancer Therapies.  They tested 24 male pleural mesothelioma patients in their 60s and 70s. They measured things like the mens’ grip strength, knee extension strength, and how far they could walk in six minutes. They also ran several tests on their lung function. They compared these test results with the patients’ own assessment of their outcomes.  The study suggests that patients who undergo P/D surgery can continue to improve beyond the postoperative phase. It is a hopeful message for patients and … Continue reading Pleural Mesothelioma Patients are Stronger a Year After Surgery »

Neoadjuvant Chemotherapy Plus Surgery for Pleural Mesothelioma: A Prospective Study

neoadjuvant chemotherapy

A new prospective Japanese mesothelioma study shows the potentially life-saving benefits of undergoing neoadjuvant chemotherapy followed by surgery. This has been the preferred way to treat pleural mesothelioma for many years. But most of the studies on it are retrospective. This means that researchers analyze data on mesothelioma patients who already had treatment. In many cases, they are patients who have died.  The new study is one of the few prospective studies on neoadjuvant chemotherapy and mesothelioma surgery.  In a prospective study, researchers enroll patients and follow their progress through treatment.  Pleural mesothelioma is often fatal within a few months. But ninety-five percent of the study subjects who had presurgical chemotherapy followed by an operation were still alive a year … Continue reading Neoadjuvant Chemotherapy Plus Surgery for Pleural Mesothelioma: A Prospective Study »

Asbestos Bans Not a Quick Fix for Rising Mesothelioma Incidence

mesothelioma incidence

A new study is further evidence that asbestos bans are not a quick fix for the global problem of malignant mesothelioma incidence.  Researchers in China and the US just released a worldwide research study on the asbestos cancer. The study included 21 regions in 195 countries and territories and spanned 27 years.  The authors say mesothelioma incidence does decrease after asbestos bans. But the decrease can take decades. In the meantime, they say many countries need to do a better job of tracking and managing mesothelioma cases.  Asbestos and Mesothelioma Incidence Malignant mesothelioma is an aggressive cancer with a poor prognosis. Exposure to asbestos is its only known cause. People with mesothelioma often die of this cancer in less than … Continue reading Asbestos Bans Not a Quick Fix for Rising Mesothelioma Incidence »

South Korean Mesothelioma Rates Still Rising Decades After Asbestos Ban

asbestos ban

A new report out of South Korea is proof that it can take many years for mesothelioma rates to decline even after implementing an asbestos ban. Asbestos is the number one cause of malignant mesothelioma worldwide. South Korea banned asbestos in 2009. But a report in the International Journal of Environmental Research and Public Health shows the country will likely be dealing with the after-effects well into the future.  A national asbestos ban is a vital step toward fighting occupational cancer. But the new study is a sobering reminder that it cannot eliminate mesothelioma overnight.  Occupational Risk for Malignant Mesothelioma Mesothelioma can be a health hazard for anyone who ever worked with or around asbestos.  Once a worker inhales or … Continue reading South Korean Mesothelioma Rates Still Rising Decades After Asbestos Ban »

Japanese Researchers Discover ‘Novel Diagnostic Marker’ for Mesothelioma

novel diagnostic marker

A protein called CDLN15 could be a novel diagnostic marker for malignant pleural mesothelioma, allowing doctors to pinpoint asbestos cancer earlier and boost the odds of survival. That is the message from a recently published Japanese study.  Pleural mesothelioma is notoriously difficult to diagnose. It rarely causes any symptoms at all until it is in a late stage. When the symptoms do show up, they are easy to confuse with other illnesses. Earlier diagnosis of pleural mesothelioma depends on finding things that set it apart from other diseases. This novel diagnostic marker could serve as a red flag for this rare but deadly cancer.  CDLN15 as a Novel Diagnostic Marker CDLN15 stands for claudin-15. Claudins are a family of proteins … Continue reading Japanese Researchers Discover ‘Novel Diagnostic Marker’ for Mesothelioma »

Artificial Intelligence Improves Mesothelioma Diagnosis, Study Finds

artificial intelligence

There is more evidence that artificial intelligence may have a role to play in helping doctors diagnose deadly malignant mesothelioma earlier.  A study conducted at Japan’s Hyogo College of Medicine used past patient records to test a deep convolutional neural network (CDNN). This is a complex computer program designed to evaluate diagnostic criteria.  Pleural mesothelioma is a difficult cancer for doctors to diagnose. Artificial intelligence can help by quickly comparing diagnostic data to hundreds of past cases. In the Japanese study, the AI produced the most accurate mesothelioma diagnoses when combined with all of the available patient data. The Challenge of Diagnosing Mesothelioma Mesothelioma tumors grow on the membranes around internal organs. They usually come from past exposure to asbestos. … Continue reading Artificial Intelligence Improves Mesothelioma Diagnosis, Study Finds »

Get your free copy of
“Surviving Mesothelioma” Today!